文献速递心力衰竭与心肌病

沙库巴曲缬沙坦较依那普利降低心衰患者合用MRA时的高钾血症风险

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该研究为PARADIGM-HF试验的二次分析,纳入8399例慢性HFrEF患者,比较沙库巴曲缬沙坦与依那普利在合用MRA时的高钾血症风险。结果显示,基线合用MRA者中依那普利组严重高钾血症发生率更高(3.1 vs 2.2/100患者年;HR 1.37;HR 1.43;

要点

  • HFrEF患者合用MRA时,沙库巴曲缬沙坦较依那普利降低严重高钾血症风险。

核心结论

  • 在合用MRA的症状性HFrEF患者中,依那普利治疗较沙库巴曲缬沙坦更易发生严重高钾血症。
  • 数据提示脑啡肽酶抑制可减轻MRA与其他RAAS抑制剂联用时的B高钾血症风险。

研究设计与样本

  • PARADIGM-HF试验的二次分析,随机分配8399例慢性HF、NYHA II-IV级、LVEF≤40%的患者。
  • 患者接受依那普利10mg每日两次或沙库巴曲缬沙坦97/103mg每日两次,MRA使用由研究者决定。
  • 每次访视测量血清钾,采用时间更新Cox比例风险模型分析高钾血症风险。

主要发现

  • 基线合用MRA者中,两组总体高钾血症发生率相似。

关键数值与推荐

  • 高钾血症定义为血钾>5.5 mEq/L,严重高钾血症定义为血钾>6.0 mEq/L。
  • 基线未用MRA者3728例(44.4%),基线用MRA者4671例(55.6%)。

临床怎么用

  • 对HFrEF患者合用MRA时,选用沙库巴曲缬沙坦可能较依那普利降低严重高钾血症风险。
  • 仍需按指南监测血钾和肾功能,并根据个体情况调整MRA剂量。

局限性

  • MRA使用非随机分配,由研究者决定,可能存在混杂。
  • 为PARADIGM-HF试验的二次分析,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin-angiotensin-aldosterone system increases the risk of hyperkalemia. OBJECTIVE: To determine whether the risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/valsartan in comparison with enalapril. DESIGN, SETTING, AND PARTICIPANTS: The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40% or less to treatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice daily (previously known as LCZ696 [200 mg twice daily]) in addition to guideline-directed medical therapy. Use of MRAs was encouraged but left to the discretion of study investigators. Serum potassium level was measured at every study visit. The incidence of hyperkalemia (potassium level >5.5 mEq/L) and severe hyperkalemia (potassium level >6.0 mEq/L) among patients treated or not treated with an MRA at baseline and the risk of subsequent hyperkalemia for those newly treated with an MRA during study follow-up were defined in time-updated Cox proportional hazards models. Analyses were conducted between August 1 and October 15, 2016. MAIN OUTCOMES AND MEASURES: Incident hyperkalemia and severe hyperkalemia. RESULTS: In comparison with the 3728 patients (44.4% of enrolled participants [21.6% female]) not taking an MRA at baseline, the 4671 patients (55.6% [22.0% female]) taking an MRA tended to be younger, with a lower EF, lower systolic blood pressure, and more advanced HF symptoms. Among those taking an MRA at baseline, the overall rates of hyperkalemia were similar between treatment groups, but severe hyperkalemia was more common in patients randomly assigned to enalapril than to sacubitril/valsartan (3.1 vs 2.2 per 100 patient-years; HR, 1.37 [95% CI, 1.06-1.76]; P = .02). In analyses including patients who newly started taking MRAs during the PARADIGM-HF trial, severe hyperkalemia remained more common in those randomly assigned to enalapril than to those randomly assigned to sacubitril/valsartan (3.3 vs 2.3 per 100 patient-years; HR, 1.43 [95% CI, 1.13-1.81]; P = .003). CONCLUSIONS AND RELEVANCE: Among MRA-treated patients with symptomatic HFrEF, severe hyperkalemia is more likely during treatment with enalapril than with sacubitril/valsartan. These data suggest that neprilysin inhibition attenuates the risk of hyperkalemia when MRAs are combined with other inhibitors of the renin-angiotensin-aldosterone system in patients with HF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01035255.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai AS, Vardeny O, Claggett B, et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017. PMID: 27842179. doi:10.1001/jamacardio.2016.4733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。